Therapeutic HPV DNA vaccines

Ken Lin, Elena Roosinovich, Barbara Ma, Chien Fu Hung, T. C. Wu

Research output: Contribution to journalReview articlepeer-review

84 Scopus citations


It is now well established that most cervical cancers are causally associated with HPV infection. This realization has led to efforts to control HPV-associated malignancy through prevention or treatment of HPV infection. Currently, commercially available HPV vaccines are not designed to control established HPV infection and associated premalignant and malignant lesions. To treat and eradicate pre-existing HPV infections and associated lesions which remain prevalent in the U.S. and worldwide, effective therapeutic HPV vaccines are needed. DNA vaccination has emerged as a particularly promising form of therapeutic HPV vaccines due to its safety, stability and ability to induce antigen-specific immunity. This review focuses on improving the potency of therapeutic HPV vaccines through modification of dendritic cells (DCs) by [1] increasing the number of antigen-expressing/antigen-loaded DCs, [2] improving HPV antigen expression, processing and presentation in DCs, and [3] enhancing DC and T cell interaction. Continued improvement in therapeutic HPV DNA vaccines may ultimately lead to an effective DNA vaccine for the treatment of HPV-associated malignancies.

Original languageEnglish (US)
Pages (from-to)86-112
Number of pages27
JournalImmunologic Research
Issue number1-3
StatePublished - Jul 2010


  • Cervical cancer
  • DNA vaccines
  • HPV
  • HPV E6
  • HPV E7
  • Therapeutic vaccine

ASJC Scopus subject areas

  • Immunology


Dive into the research topics of 'Therapeutic HPV DNA vaccines'. Together they form a unique fingerprint.

Cite this